首页> 美国卫生研究院文献>Journal of Clinical Medicine >Present and Future of Bronchopulmonary Dysplasia
【2h】

Present and Future of Bronchopulmonary Dysplasia

机译:支气管肺发育不良的现状和未来

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Bronchopulmonary dysplasia (BPD) is the most common respiratory disorder among infants born extremely preterm. The pathogenesis of BPD involves multiple prenatal and postnatal mechanisms affecting the development of a very immature lung. Their combined effects alter the lung’s morphogenesis, disrupt capillary gas exchange in the alveoli, and lead to the pathological and clinical features of BPD. The disorder is ultimately the result of an aberrant repair response to antenatal and postnatal injuries to the developing lungs. Neonatology has made huge advances in dealing with conditions related to prematurity, but efforts to prevent and treat BPD have so far been only partially effective. Seeing that BPD appears to have a role in the early origin of chronic obstructive pulmonary disease, its prevention is pivotal also in long-term respiratory outcome of these patients. There is currently some evidence to support the use of antenatal glucocorticoids, surfactant therapy, protective noninvasive ventilation, targeted saturations, early caffeine treatment, vitamin A, and fluid restriction, but none of the existing strategies have had any significant impact in reducing the burden of BPD. New areas of research are raising novel therapeutic prospects, however. For instance, early topical (intratracheal or nebulized) steroids seem promising: they might help to limit BPD development without the side effects of systemic steroids. Evidence in favor of stem cell therapy has emerged from several preclinical trials, and from a couple of studies in humans. Mesenchymal stromal/stem cells (MSCs) have revealed a reparatory capability, preventing the progression of BPD in animal models. Administering MSC-conditioned media containing extracellular vesicles (EVs) have also demonstrated a preventive action, without the potential risks associated with unwanted engraftment or the adverse effects of administering cells. In this paper, we explore these emerging treatments and take a look at the revolutionary changes in BPD and neonatology on the horizon.
机译:支气管肺发育不良(BPD)是极早产儿中最常见的呼吸系统疾病。 BPD的发病机制涉及多种产前和产后机制,影响非常不成熟的肺的发育。它们的综合作用改变了肺的形态,破坏了肺泡中的毛细气体交换,并导致了BPD的病理和临床特征。该疾病最终是由于对发育中的肺的产前和产后损伤的异常修复反应所致。新生儿科在处理与早产有关的疾病方面取得了巨大进展,但是迄今为止,预防和治疗BPD的努力仅部分有效。鉴于BPD似乎在慢性阻塞性肺疾病的早期起源中起作用,因此BPD的预防在这些患者的长期呼吸结果中也至关重要。当前有一些证据支持使用产前糖皮质激素,表面活性剂治疗,无创通气,靶向性饱和,早期咖啡因治疗,维生素A和体液限制,但现有策略均未对减轻患者的负担产生任何重大影响。 BPD。然而,新的研究领域正在开拓新的治疗前景。例如,早期局部用药(气管内或雾化)类固醇似乎很有希望:它们可能有助于限制BPD的发生而没有全身性类固醇的副作用。多项临床前试验以及一些针对人体的研究都提出了支持干细胞疗法的证据。间充质基质/干细胞(MSC)具有修复能力,可防止BPD在动物模型中进展。含有细胞外囊泡(EV)的MSC条件培养基的给药也显示出预防作用,而没有与不希望的植入相关的潜在风险或给药细胞的不利影响。在本文中,我们探索了这些新兴疗法,并展望了BPD和新生儿医学的革命性变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号